Press Release: AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025
AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025 Sydney, Australia – October 13, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, announces a presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in…
Dover, DE, Oct. 12, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON) stated that during the market conditions of the past week, AlphaTON Capital is still expanding its TON Treasury, purchasing an additional 300,000 TON off the open market today, adding to the 1.1million TON purchased off the open market last week. With zero…
New Orleans, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Babak J. Mehrara, MD, has been named president of The Plastic Surgery Foundation (The PSF), an organization that supports the research and international activities of the American Society of Plastic Surgeons (ASPS). He officially assumed his role Oct. 12, 2025, at Plastic Surgery The Meeting, the Society's…
NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Nutex Health Inc. (“Nutex” or “the Company”) (NASDAQ: NUTX) and certain of its officers.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Semler Scientific To Contact Him Directly To Discuss Their Options If you suffered losses in Semler Scientific between March 10, 2021 and April 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson…
